Inoperable or metastatic PSMA-expressing cancer, with significant PSMA expression defined as uptake in at least one lesion that is superior to that of the liver on PSMA positron-emission tomography (PET) within 3 months prior to enrolment
Cancer progression documented within 3 months prior to enrolment as per the investigator's assessment, without initiation of another anti-cancer treatment since (excluding palliative radiation therapy to a minority of the tumor burden), unless that anti-cancer treatment was stopped prematurely because of intolerance
For participants with a cancer other than mCRPC, a recommendation from a multidisciplinary tumor board (MDT) in favor of PSMA RPT must be obtained
You may not be if
Platelets \< 50 x 106/L
Absolute neutrophil count (ANC) \< 1.0 x 106/L
Eastern Cooperative Oncology Group (ECOG) 4 or prognosis \< 3 months, for cancer-related or other serious medical conditions, as per investigator's assessment
Known presence of central nervous system metastasis at risk of complication, which cannot be adequately stabilized (e.g. radiotherapy or corticoid prophylaxis), as per investigator's assessment
Any condition that would limit the ability to comply with the study protocol, as per investigator's assessment
Pregnancy or breastfeeding (e.g. for female participants with non-prostate cancer)
Clareo Health | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
